

What is dysarthric speech ? The neurologist' point of view



Aix en Provence, the 29th of June 2010


Canan Ozsancak

Questions of the neurologist

1. Is it dysarthria ?
2. Can it help me for the neurological diagnosis ?
3. Does it help us to understand brain function ?
4. How should I analyse dysarthria ?
5. How do I treat it ?

Q1. Is it dysarthria ?

What is dysarthria ?



Check list

- Is the problem **neurologic** ?
- If the problem is not neurologic, is it nonetheless **organic** ?
For example, is it due to dental or occlusion abnormality, mass lesion of the larynx or is it psychogenic ?
- If the problem is or is not neurologic, is it **recently acquired or longstanding** ? For example, might it reflect unresolved developmental stuttering, articulation disorder or language disability ?
- If the problem is neurologic, is it a **MSD** or another neurologic disorder that is affecting verbal expression (aphasia, akinetic mutism ?)
- If a MSD is present, is it a **dysarthria** or apraxia of speech ?
- If dysarthria is present, what is its **type** ?

Duffy JR (2005)

What is dysarthria ?



- Great heterogeneity
 - Severity
 - Numerous etiologies

Q2 : aid for the diagnosis ?

- Most neurologists think that they can recognize the type of dysarthria just by listening, but
 - Perceptual classification studies are insufficient
 - Zyski et al.
 - 16 parameters : 20%, 3 parameters : 55%
 - Ozsancak et al. (2006) :
 - PD vs CBD vs Controls : 47% vs 37 % vs 93%
 - Fonville et al. (2008)
 - Neurologists = Residents ≈ 35 %
 - Van der Graal et al. (2009)
 - Neurologists = Residents = Speech therapists ≈ 40 %
- ⇒ Diagnosis based on perceptual features is weak
- ⇒ It is generally based on the context of other disturbances at the neurological examination or imaging

When dysarthria is the prominent symptom

- ALS
- Myasthenia gravis



When speech is atypical for a given condition

- Too severe, too early : PSP, MSA
- Concomittant abnormalities :
 - Stridor (MSA), involuntary sighs or palilalia (PSP), orofacial apraxia (CBD)

Q3. Does it help us to understand brain function ?

Q3. Does it help us to understand brain function ?

- Functional imaging
- Instrumental analysis




Q3. Does it help us to understand brain function ?

- *Neural plasticity*
Kleim and Jones
- *Neural plasticity and speech*
Ludlow et al.

JSHR 2008

Neural plasticity : 10 rules of Kleim and Jones


1. Use it or lose it
2. Use it and improve it
3. Specificity
4. Repetition matters
5. Intensity matters
6. Time matters
7. Salience matters
8. Age
9. Transference
10. Interference



Neural plasticity and speech

- *Does oromotor strength training transfer to aid the return of speech production ?*
- *Do training paradigms developed for spinal systems pertain to craniofacial bulbar systems ?*
- *Can speech production skills be relearned in brain-injured adults ?*
- *Should emphasis be placed on invoking alternate brain mechanisms for speech recovery or is the return of function needed in the original substrates?*

Neural plasticity and dysarthria



- Liotti et al. Neurology 2003, 60 : 432-440.

Q4. How do I analyse my patient's dysarthria ?

Q4. How do I analyse my patient's dysarthria ?


- A. The clinical questions
- B. Understanding underlying pathogeny
- C. Tools
 - Clinical
 - Instrumental analysis

The clinical questions

- How severe is the patient's dysarthria ?
- How to describe the speech of the patient ?
- What is the underlying dysfunction of the speech effectors ?
- What does the patient think about his speech ?

Self assessment of dysarthria

Principales plaintes



Hartelius & Svenson, 1994

Voice Handicap Index

	J	PJ	P	PT	T
F1		X			
P2		X			
F3		X			
P4	X				
F5			X		
F6	X				
E7					
F8				X	
E9		X			
P10	X				
F11		X			
F12	X				
P13		X			
P14				X	
E15				X	
F16	X				
P17		X			
P18		X			
F19		X			
P20			X		
P21		X			
F22		X			
E23			X		
E24	X				
E25		X			
P26			X		
E27		X			
E28			X		
E29		X			
E30	X				

3 domains

- physical : 10 items
- functional : 10 items
- emotional : 10 items

Total : 120 pts

Score ↑ ⇒ Handicap ↑

Jacobson et al., 1997

Q5. How do I treat dysarthric patients ?

Dysarthria and treatment

- When to treat ?
 - Vascular :
 - spontaneous regression...
 - Parkinson :
 - Too often late SLT
 - Arguments for an early start
- How to treat ?
 - Drugs
 - SLT
 - Combined therapies

Table 1. Variability in the effects of levodopa on dysarthria in PD

	Improvement	Steady-state	Worsening
Intelligibility	Rigrodsky and Morrison, 1970 (21 patients; perceptual rating of speech components) ¹⁰ Fotoni et al., 1997 (nine patients, UPDRS) ¹¹ Wolfe et al., 1975 (17 patients; perceptual rating of speech components) ¹²	Quagliari and Calaisa, 1977 (30 patients; 14 without any surgery, qualitative rating of global speech) ¹³ Wolfe et al., 1975 (17 patients; perceptual rating of speech components) ¹²	Marsden and Parkes, 1976 (case reports; clinical observations) ¹⁴ Critchley, 1976 (case study; perceptual evaluation) ¹⁵ Anderson et al., 1999 (case study; perceptual count of speech dysfluencies) ¹⁶ Benke et al., 2000 (24 advanced patients; psycholinguistical tests for perceptual speech assessment) ¹⁷ Goberman et al., 2003 (nine patients; perceptual count of speech dysfluencies) ¹⁸
Laryngeal level	Mawdsley and Gamsu, 1971 (20 patients, two with previous thalamotomy, acoustical recordings for phonation duration) ¹⁹ Jiang et al., 1999 (15 patients, electroglottographic recording) ²⁰ Sanabria et al., 2001 (20 patients, acoustics for phonatory parameter analysis) ²¹ Gallera et al., 2001 (six early stage patients, laryngeal electromyography) ²² Goberman et al., 2002 (nine patients, acoustic recording for phonatory parameter analysis) ²³	Jiang et al., 1999 (15 patients; acoustics, airflow and electroglottographic recording) ²⁰ Pohla et al., 1998 (ten patients; vowel duration measurements) ²⁴	
Supralaryngeal level	Vercueil et al., 1999 (11 patients, airflow, rib cage and abdomen movements) ²⁵ Leanderson et al., 1971 (seven patients, five with previous thalamotomy, labial EMG) ²⁶ Leanderson et al., 1972 (12 patients, five studied before and after levodopa, labial EMG) ²⁷ Nakano et al., 1973 (18 patients, early introduction of levodopa, orofacial EMG) ²⁸ Cahill et al., 1998 (16 patients, lip pressure measurements) ²⁹ Svensson et al., 1993 (nine patients, jaw movement kinematics) ³⁰	Solomon and Hixon, 1993 (14 patients; 14 healthy people, chest wall kinematics and oral pressure) ³¹ De Letter et al., 2003 (ten patients; tongue force measurements) ³²	Vercueil et al., 1999 (one patient; airflow, rib cage and abdomen movements) ²⁵ Gentili et al., 1998 (14 patients; lips and tongue force measurements) ³³ Gentili et al., 1999 (case study; PD for 13 years, lips and tongue force measurements) ³⁴ De Letter et al., 2003 (ten patients; tongue force measurements) ³²

(Pinto et al. 2004) ³⁵

Table 1. Variability in the effects of levodopa on dyspraxia in PD


	Improvement	Steady-state	Worsening
Intelligibility	Rapinsky and Morrison, 1970 (21 patients, perceptual rating of speech components) Folstein et al., 1981 (190 patients, UPDRS) Wong et al., 1975 (17 patients, perceptual rating of speech components) ¹⁰	Quigley and Celsis, 1977 (50 patients, 14 without any surgery, a collective rating of global speech) ¹¹ Wills et al., 1975 (17 patients, perceptual rating of speech components) ¹²	Marsden and Parkes, 1976 (case reports, clinical observations) ¹³ Cohen, 1976 (case study, perceptual evaluation) ¹⁴ Anderson et al., 1999 (case study, perceptual count of speech dysfluencies) ¹⁵ Berke et al., 2000 (54 advanced patients, psychophysical tests for perceptual speech assessment) ¹⁶ Goberman et al., 2003 (190 patients, perceptual count of speech dysfluencies) ¹⁷
Laryngeal level	Mowlesley and Ganss, 1974 (20 patients, two with previous thymotomy, acoustic recordings for phonatory duration) ¹⁸ Jiang et al., 1999 (18 patients, electroglottographic recording) ¹⁹ Gardens et al., 2001 (20 patients, acoustics for phonatory parameter analysis) ²⁰ Galons et al., 2001 (six early stage patients, laryngeal electromyography) ²¹ Goberman et al., 2002 (190 patients, acoustic recording for phonatory parameter analysis) ²²	Jiang et al., 1999 (15 patients, acoustics, airflow and electromyographic recordings) ¹⁹ Pulhe et al., 1998 (ten patients, visual duration measurements) ²³	Verouel et al., 1999 (one patient, airflow, rib cage and abdomen movements) ²⁴ Curti et al., 1998 (14 patients, lip and tongue force measurements) ²⁵ Gent et al., 1999 (case study, PD for 15 years, lip and tongue force measurements) ²⁶ De Letter et al., 2003 (ten patients, tongue force measurements) ²⁷
Supralaryngeal level	Verouel et al., 1999 (11 patients, airflow, rib cage and abdomen movements) ²⁴ Lunderson et al., 1971 (seven patients, five with previous thymotomy, labial EMG) ²⁸ Lunderson et al., 1972 (15 patients, five studied before and after levodopa, labial EMG) ²⁹ Nakano et al., 1978 (18 patients, early introduction of levodopa, ventral EMG) ³⁰ Curti et al., 1998 (14 patients, lip and tongue force measurements) ²⁵ Shawarid et al., 1993 (190 patients, jaw movement kinematics) ³¹	Solomon and Ikin, 1995 (14 patients, 14 healthy people, chest wall kinematics and oral pressure) ³² De Letter et al., 2003 (ten patients, tongue force measurements) ²⁷	Verouel et al., 1999 (one patient, airflow, rib cage and abdomen movements) ²⁴ Curti et al., 1998 (14 patients, lip and tongue force measurements) ²⁵ Gent et al., 1999 (case study, PD for 15 years, lip and tongue force measurements) ²⁶ De Letter et al., 2003 (ten patients, tongue force measurements) ²⁷

+ ?


LSVT-Loud®

Conclusion


Dysarthria in clinic



Dysarthria in clinic : the point of view of the neurologist



The neurologist and MSD research



- 2 examples :
 - Classification of types of dysarthria
 - SLT : LSVT®

